The seventh batch of national procurement is continuing to land, and there are many clear implementation times!

【Pharmaceutical Network Industry News】The results of the seventh batch of national procurement will be implemented in November 2022, and many places have successively begun to start preliminary work
for the solid implementation of the seventh batch of national procurement.
This week, a number of documents were issued, making it clear that the results
of the election will be officially implemented in November.
On October 25, the Shanxi Provincial Medical Insurance Bureau issued the Notice on Fully Implementing the Selection Results of the Seventh Batch of State-Organized Centralized Drug Procurement, clarifying that the results of the seventh batch of national procurement will be implemented from November 20, 2022
.
The scope of institutions involved includes all public medical institutions, military medical institutions, and voluntary participation in medical insurance designated social medical institutions and designated pharmacies
.
The notice clarifies that the agreed procurement volume and procurement cycle of the seventh batch of selected products in the first year shall be determined
in accordance with the relevant rules in the "National Centralized Drug Procurement Document" (GY-YD2022-1) issued by the National Joint Procurement Office.
The agreed procurement volume shall be calculated and approved
by the Provincial Centralized Bidding and Procurement Center for Pharmaceuticals and Equipment based on relevant data such as relevant procurement documents and selection results.
Purchase agreements are signed
once a year during the procurement cycle.
When renewing the purchase agreement, the agreed purchase quantity shall in principle not be less than the agreed purchase quantity
of the selected product in the previous year.
If the agreed purchase volume of the current year is completed in advance during the procurement cycle, the excess selected enterprises will still supply according to the selected price until the expiration
of the procurement cycle.
On October 24, the Qinghai Provincial Medical Insurance Bureau also issued a document clarifying that the results of the seventh batch of national procurement will be implemented from November 1, 2022, and all pharmaceutical institutions participating in centralized procurement in the province will implement them uniformly, and at the same time, the relevant implementation policies
for prepared drugs will be clarified 。 On July 18 this year, the seventh batch of national procurement announced the results of the selection, this time the procurement of 60 drugs was successful, the average price of the selected drugs was reduced by 48%, involving 31 treatment categories, not only including hypertension, diabetes, anti-infection, digestive tract diseases and other common diseases, chronic diseases, but also lung cancer, liver cancer, kidney cancer, bowel cancer and other major diseases of drugs, according to the agreed procurement measurement, it is expected to save 18.
5 billion yuan
per year.
At present, including Shanxi and Qinghai, at least 18 provinces and cities have issued documents to implement the results
of the seventh batch of national collective procurement.
Among them, 8 provinces (cities) including Henan, Qinghai, Gansu, Shanxi, Hainan and Shanghai have clarified the specific implementation time, all in November
.
Since the review and approval of the "Pilot Plan for Centralized Drug Procurement by the State" in November 2018, it has been nearly 4 years since the national centralized procurement, and pharmaceutical companies have also adapted to the normalization of centralized procurement and are actively entering the market
.
In this context, there will be a large number of high-quality and low-cost products in the future that will continue to benefit the majority of patients
.
In fact, at present, the news
of the eighth batch of national procurement has been reported in the industry.
The industry expects that the implementation of the seventh batch of national procurement will be accelerated across the country, and at the same time, more and more patients will also use reduced-price drugs
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.